Limited-stage Hodgkin lymphoma: Managing uncertainty

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1180-1182

  Meyer, Ralph M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DECISION MAKING; DISEASE CONTROL; DISEASE COURSE; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RADIATION FIELD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; FEMALE; MALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; MALE;

EID: 84904723624     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.6259     Document Type: Editorial

References (17)

1. Hoppe RT: Early-stage Hodgkin's disease: A choice of treatments or a treatment of choice? J Clin Oncol 9:897-901, 1991
2. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
3. Meyer RM, Gospodarowicz MK, Connors JM, et al: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366:399-408, 2012
4. Meyer RM, Hoppe RT: Point/counterpoint: Early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 120:4488-4495, 2012
5. Raemaekers JMM, Andre MPE, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative patients with stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
6. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
7. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
8. Eich HT, Engenhart-Cabillic R, Hansemann K, et al: Quality control of involved field radiotherapy in patients with early-favorable (HD10) and earlyunfavorable (HD11) Hodgkin's lymphoma: An analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71:1419-1424, 2008
9. Hodgson DC: Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011:323-329, 2011
10. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003 (Pubitemid 46594052)
11. Sasse S, Klimm B, Görgen H, et al: Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol 23:2953-2959, 2012
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
13. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
14. Radford J, Barrington S, Counsell N, et al: Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID Trial. Blood 120:547, 2012
15. Eichenauer DA, Engert A: Advances in the treatment of Hodgkin lymphoma. Int J Hematol 96:535-543, 2012
16. Hay AE, Klimm B, Chen BE, et al: An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 24:3065-3069, 2013
17. Hay AE, Meyer RM: Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: The role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone. Hematol Oncol Clin North Am 28:49-63, 2014